The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding.

Kim A ConnellyEllen WuAylin VisramMark K FriedbergSri Nagarjun BatchuVeera Ganesh YerraKerri ThaiLinda NghiemYanling ZhangGolam KabirJ F DesjardinsAndrew AdvaniRichard E Gilbert

Published in: Cardiovascular drugs and therapy (2022)

Dapagliflozin reduces the structural, functional, and molecular manifestations of right ventricular pressure overload. Whether amelioration of these early changes in the RV may ultimately lead to a reduction in RV failure remains to be determined.

Keyphrases

mycobacterium tuberculosis
pulmonary artery
coronary artery
pulmonary hypertension
pulmonary arterial hypertension
single molecule